A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

September 26, 2026 updated by: Bambusa Therapeutics

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.

Study Type

Interventional

Enrollment (Estimated)

237

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Recruiting
        • Fremantle Dermatology
      • Perth, Western Australia, Australia, 6009
        • Completed
        • Linear Clinical Research
      • Christchurch, New Zealand
        • Recruiting
        • Optimal Clinical Trials Ltd - Christchurch
      • Upper Hutt, New Zealand, 5018
        • Recruiting
        • Pacific Clinical Research Network (PCRN) Wellington
        • Contact:
          • Tim Humphrey
    • Auckland
      • Grafton, Auckland, New Zealand, 1010
        • Recruiting
        • Optimal Clinical Trials Central Auckland
        • Contact:
          • Arna Letica
      • Otahuhu, Auckland, New Zealand, 2025
        • Withdrawn
        • Aotearoa Clinical Trials
      • Takapuna, Auckland, New Zealand, 0622
        • Recruiting
        • Pacific Clinical Research Network (PCRN) - Auckland
        • Contact:
          • Paul Hamilton
      • Lodz, Poland, 91-347
        • Recruiting
        • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
      • Rzeszów, Poland, 35-055
        • Recruiting
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Warsaw, Poland, 02-507
        • Recruiting
        • Państwowy Instytut Medyczny MSWiA
      • Wroclaw, Poland, 50-566
        • Recruiting
        • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
    • California
      • Irvine, California, United States, 92614
        • Recruiting
        • First OC Dermatology
    • New York
      • New York, New York, United States, 10128
        • Recruiting
        • OptiSkin Medical
      • The Bronx, New York, United States, 10455
        • Recruiting
        • Equity Medical, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 72 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Key Inclusion Criteria

  1. Negative pregnancy tests for women of childbearing potential.
  2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
  3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
  4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

  1. Age of 18-65 years.
  2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
  3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

  1. Age of 18-72 years.
  2. Body mass index ≥16 kg/m², weight capped at 125 kg.
  3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
  4. Moderate to severe atopic dermatitis
  5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
  6. Atopic lesions cover ≥10% of body surface area (BSA)
  7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
  5. Abnormal Electrocardiogram (ECG) findings
  6. History of drug/alcohol abuse in the past 2 years.
  7. Donated >500mL blood within 2 months of screening.
  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
  2. Receipt of immunoglobulin or blood products within 30 days.
  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
  4. Chronic pruritus from conditions other than atopic dermatitis.
  5. Acute/treated infections or chronic skin infections.
  6. Current use of sedating antihistamines or corticosteroids.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Experimental: Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

BBT001 will be administered

Experimental: Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo Comparator: Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

Placebo will be administered

Placebo Comparator: Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

Placebo will be administered

Placebo Comparator: Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Active Comparator: Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Placebo Comparator: Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

Placebo will be administered

Active Comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo Comparator: Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Active Comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

BBT001 will be administered

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with adverse events following single and multiple administration of BBT001
Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in serum blood parameters
Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Laboratory assessments include hematology, blood chemistry and coagulation test

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in vital sign measurements following treatment administration.
Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Blood pressure and heart rate will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in physical examination following treatment administration.
Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Physical examination will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in 12-lead ECG readings
Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

12-lead ECG will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Maximum observed concentration of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum PK Tmax will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Area under the curve (AUC)
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Area under the curve of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Volume of distribution (Vz)
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Volume of distribution of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Total clearance (CL)
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Total clearance of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Elimination half-life of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Time Frame: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum Anti-Drug Antibodies will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Lisa Li, Bambusa Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 27, 2025

Primary Completion (Estimated)

February 28, 2027

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

January 30, 2025

First Submitted That Met QC Criteria

January 30, 2025

First Posted (Actual)

February 5, 2025

Study Record Updates

Last Update Posted (Actual)

September 29, 2026

Last Update Submitted That Met QC Criteria

September 26, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe